Please assess the completion status of the following clinical trial:

Trial Title: Defective Atypical Protein Kinase C (PKC) Activation in Diabetes and Metabolic Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Stable uncomplicated type 2 diabetes~* Able to be off oral treatments for 2 months~Exclusion Criteria:~* Diabetic complications related to heart, eye, nerve problems~* Renal impairment~* Cardiovascular disease~* Hepatic disease~* Prior history of other disorders or complications caused by diseases~* Insulin therapy needed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Group 1 (Type: None): type 2 diabetic individuals
- Group 2 (Type: None): type 1 diabetic individuals or those with diabetes secondary to pancreatic disease
- Group 3 (Type: None): non-diabetic individuals who are not considered to be overweight
- Group 4 (Type: None): non-diabetic individuals who are considered to be overweight
- Group 5 (Type: None): non-diabetic and type 2 diabetic individuals who will be subjected to an exercise study
- Group 6 (Type: None): individuals who have or are suspected of having glucose intolerance, including patients who have a history of gestational diabetes and patients who have polycystic ovary syndrome
- Group 7 (Type: None): healthy non-diabetic subjects who will receive one dose of metformin orally 1-2 hours before performing procedures

Based on this trial design, predict the completion outcome and termination type (if applicable).